The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment patterns, genomic characteristics, and outcomes among patients with metastatic lobular breast cancer.
 
Sherry Shen
Honoraria - MJH Life Sciences
Research Funding - Merck (Inst); Sermonix Pharmaceuticals (Inst)
 
Fresia Pareja
Consulting or Advisory Role - AstraZeneca; MultiplexDx
 
Charlie White
No Relationships to Disclose
 
Yuan Chen
No Relationships to Disclose
 
Anton Safonov
No Relationships to Disclose
 
Pedram Razavi
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Loxo/Lilly; Myriad Genetics; NeoGenomics Laboratories; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - AstraZeneca (Inst); Biovica (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Hologic/Biotheranostics (Inst); Illumina (Inst); Invitae (Inst); Myriad Genetics (Inst); NeoGenomics Laboratories (Inst); Novartis (Inst); Tempus (Inst)
 
Chau Dang
Consulting or Advisory Role - Daichii Sankyo; Gilead Sciences; Novartis; Pfizer; Race Oncology; ROCHE/Genentech; Seagen
Research Funding - Genentech/Roche (Inst)
Travel, Accommodations, Expenses - ROCHE/Genentech
 
Komal Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Gilead Sciences; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Context Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); RayzeBio (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical